Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To evaluate the clinical efficacy of carumonam (CRMN, AMA-1080), the drug was used in the treatment of 10 patients including 4 with pneumonia and each with acute tonsillitis, chronic bronchitis, Mycoplasma pneumonia, primary atypical pneumonia (PAP), chronic pyelitis, and acute cystitis. Since beta-lactam antibiotics were not active against Mycoplasma pneumonia and PAP, these diseases were excluded from the clinical efficacy evaluation of CRMN. Responses were excellent in 1 patient and good in 7. Side effects were not observed. The laboratory test recognized slight elevations of GOT, GPT and eosinophilia in 1 patient and a slight leucopenia in another upon the administration of CRMN.
 ...
PMID:[Clinical study of carumonam]. 344 30

Fourteen caesarean-derived, colostrum-deprived pigs and seven conventional swine were exposed to low passage, cloned, field isolates of Mycoplasma flocculare. Sera were collected at varying intervals postexposure (PE) and tested against M. flocculare and M. hyopneumoniae antigens in a semi-automated ELISA. Swine were killed six to 17 weeks PE and their lungs examined grossly for lesions and culturally for mycoplasmas. Pure cultures of M. flocculare were recovered from the lungs of 11 of 14 swine killed six to 12 weeks PE. Mycoplasmas were not isolated from the swine killed 15 to 17 weeks PE. Only one pig had gross lesions of pneumonia. Immunoassays revealed that swine were slow to seroconvert and titers (expressed in terms of optical density) were low. Three of 21 swine had antibodies to M. flocculare five weeks PE, five of 17 had seroconverted at seven to eight weeks and all surviving swine had antibodies to M. flocculare 76 days PE and beyond. Net optical density of positive sera was in the range of 0.201 to 0.412 (an optical density of 0.2 regarded as the breakpoint between negative and positive reactions in our ELISA). All of the sera were ELISA-negative when tested against M. hyopneumoniae antigen. This is regarded as a very significant finding. There has been concern that field sera might contain antibodies to M. flocculare and that such antibodies could render serodiagnostic tests for mycoplasmal pneumonia of swine nonspecific. Results of the present study suggest that swine infected with M. flocculare do not develop sufficient levels of antibodies to interfere with enzyme immunoassays for M. hyopneumoniae.
 ...
PMID:Serological, pathological and cultural evaluations of swine infected experimentally with Mycoplasma flocculare. 360 50

We treated pneumonia due to anaerobic bacteria, Mycoplasma pneumonia, and other type of pneumonia with clindamycin-2-phosphate (CLDM-P) and studied the distribution of the drug into pleural effusion. The obtained results are summarized as follows. 1. CLDM-P showed excellent effects in all the treated cases of pneumonia due to anaerobic bacteria and Mycoplasma pneumonia. But the success rate was 50% in cases of other type of pneumonia. We suggest that the drug must be used in due consideration of the types of causative bacteria. 2. Five cases which had developed pleural effusions were treated with intravenous drip of CLDM-P 1,200 mg in 200 ml electrolytic solution to see the distribution into pleural effusions. The results showed that the distribution ratio was 9.0% on the average. Peak levels were 1.86-6.07 micrograms/ml and the concentration was as high as 1.28 micrograms/ml on the average 24 hours after administration.
 ...
PMID:[Clindamycin-2-phosphate in the treatment of respiratory infections and its distribution into pleural effusion]. 361 89

Cefuzoname (CZON, L-105) a newly developed cephalosporin, has broad spectrum on Gram-positive or -negative bacteria and may also be effective against Staphylococcus aureus against which third generation cephalosporins are largely ineffective. We studied the pharmacokinetics and clinical effects of CZON on infectious disease of children. The diseases we studied included 2 cases of bacterial meningitis and 1 case each of viral meningitis, enterocolitis, upper respiratory infection, pneumonia, and mycoplasmal pneumonia. CZON was administered by drip infusion. Dose levels were 20-53 mg/kg/30-60 minutes, 3 times a day. For 5 cases, was studied time course of concentrations of CZON in plasma. Median T 1/2 was 0.96 hour. Concentrations in cerebrospinal fluid (CSF) were studied in cases of pneumonia and bacterial meningitis. In the case of pneumonia the CSF concentration of CZON was 0.272 microgram/ml after 45 minutes, in the case of meningitis they were 0.155 microgram/ml after 5 hours. Both of these values were higher than MIC of 0.025 microgram/ml against Haemophilus influenzae which was isolated from a case of bacterial meningitis. This MIC was lower than that of cefotiam and cefazolin, as well as of cefmenoxime. Clinical effects were excellent on pneumonia, good on upper respiratory infection, fair on mycoplasmal pneumonia. CZON, however, was ineffective in the treatment of a case of bacterial meningitis from which a susceptible strain of H. influenzae was isolated.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Studies on cefuzoname in the field of pediatrics]. 361 97

Pathologic descriptions of Mycoplasma pneumoniae pneumonia in humans are scarce, and most descriptions are from autopsy studies. We studied open lung biopsy specimens from six patients with proved or probable M pneumoniae pneumonia and reviewed the findings on M pneumoniae pneumonia that have been reported in the literature, as well as the electron microscopic characteristics of the organism, to document the morphologic spectrum. Five of our six cases showed a typical but nonspecific polymorphonuclear leukocyte-rich exudate in the bronchiolar lumina, metaplastic cells that lined the bronchioles, a lymphoplasmacytic bronchiolar wall infiltrate, peribronchiolar septal widening, and adjacent hyperplasia of type II pneumocytes. In one patient, diffuse alveolar damage was superimposed on the above bronchiolar lesion, and the sixth patient had a nonspecific organizing pneumonia.
 ...
PMID:Open lung biopsy in Mycoplasma pneumoniae pneumonia. 375 67

A newly developed cephalosporin, cefixime (CFIX), was evaluated clinically in 35 pediatric patients. A pharmacokinetic study was also performed with 11 patients. CFIX was administered as granules. The pharmacokinetic study was conducted in 11 patients, each of 6 patients was given CFIX at a dose of 3 mg/kg and each of the remaining patients was given CFIX at 6 mg/kg. Serum concentrations of CFIX were measured at 2, 4, 6, 8 and 12 hours after dosing. Urinary concentrations of CFIX were measured for periods of 0-6 and 6-12 hours after dosing. CFIX was assayed by the disk method using E. coli ATCC 39188 as the test organism. The clinical evaluation was conducted in 35 children including 5 patients of acute tonsillitis, 10 of acute lacunar tonsillitis, 1 of purulent lymphadenitis, 1 of scarlet fever, 8 of acute bronchitis, 5 of pneumonia, 3 of urinary tract infections and 1 of paratyphoid B. One additional patient was included only in the evaluation of safety since he was suffering from Mycoplasma pneumonia. the patients were from 4 months to 8 years 2 months old and 11 of them were inpatients. Daily doses were from 6.0 to 13.5 mg/kg. After CFIX administration in doses of 3 mg/kg and 6 mg/kg, peak serum concentrations were 1.75 and 3.36 micrograms/ml, half-lives were 2.65 and 2.86 hours and urinary excretions rates up to 12 hours after dosing were 16.1 and 12.4%, respectively. Serum concentrations were dose dependent and the half-life was fairly long compared with other known oral cephalosporins. Clinical efficacies of CFIX in 34 patients were "excellent" in 25 children, "good" in 8 and "poor" in 1 with effectiveness rate of 97.1%. Twenty-two strains of causative organisms, including 6 strains of S. aureus, 3 of S. pyogenes, 2 of S. pneumoniae, 3 of E. coli, 5 of H. influenzae, 2 of H. parainfluenzae and 1 of S. paratyphi B, were isolated. After treatment all strains except 2 strains of S. aureus (one was unknown and the other was decreased), 1 strain of S. pneumoniae (unknown) and 1 strain of H. influenzae (unknown) were successfully eradicated but S. paratyphi B was proved again in feces 9 days after treatment. No adverse reaction was observed. Among 18 children who went through laboratory test, however, an elevation of eosinophile and elevations of GOT and GPT were observed in 2 children and 1 child, respectively.
 ...
PMID:[Clinical studies of cefixime granules in pediatrics]. 376 35

Bacteriological, pharmacokinetic, and clinical studies of cefixime (CFIX), a newly developed oral cephalosporin, was conducted in our pediatric department as outlined below. Bacteriology The prevalent MICs of CFIX by microbiological species, compared with those of the reference drugs, were detailed below. Against 16 strains of S. aureus, the MICs averaged 6.25 micrograms/ml, and were found to be nearly the same as the MICs of amoxicillin (AMPC) but higher than those of cephalexin (CEX) and cefaclor (CCL). For 4 strains of S. pyogenes, the MICs averaged 0.05 microgram/ml, and were higher than the MICs of AMPC but lower than those of CEX and CCL. Mean MICs of CFIX against other clinical isolates were lower than those of CEX, CCL, or AMPC; E. coli (20 strains), 3.13 micrograms/ml; K. pneumoniae (9), 0.10 microgram/ml; P. mirabilis (16), 0.025 microgram/ml; P. vulgaris (5), 0.10 microgram/ml; H. influenzae (11), 0.05 microgram/ml; and S. typhimurium (4), 0.10 microgram/ml. The MICs of CFIX against 10 strains of P. aeruginosa were distributed at and above 25 micrograms/ml, a range much lower than greater than or equal to 100 micrograms/ml for CEX, CCL, or AMPC. Pharmacokinetics The serum concentrations and urinary recovery were studied in 3 children ranging from age 7 to 13. They were given CFIX on empty stomach in 2 different single doses of 3 and 6 mg/kg in a cross-over design. Average serum CFIX concentrations were dose-dependent, as evidenced by the respective peak concentrations of 1.70 microgram/ml for a 3 mg/kg dosage and 2.72 micrograms/ml for 6 mg/kg, which were attained 4 hours after the administration of the drug. The average half-lives of CFIX in the serum were 3.09 hours and 3.11 hours, respectively, and the 12-hour serum concentrations were 0.32 microgram/ml and 0.77 microgram/ml, respectively, for the 2 different dose levels. The average 12-hour urinary recovery was 25.2% and 22.3%, respectively. Clinical study Clinical effectiveness, bacteriological effectiveness, and side effects were studied in 27 children with infection including 4 patients with acute pharyngitis, 13 with acute purulent tonsillitis, 5 with acute pneumonia, 3 with urinary tract infection, and 1 each with acute rhinitis and acute bronchitis. One child with acute pneumonia (Mycoplasma pneumonia) was excluded from the study. The therapeutic effectiveness was "excellent" in 21, "good" in 3, "fair" in 1, and "poor" in 1, with an effectiveness rate of 92.3%.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Fundamental and clinical studies on cefixime in pediatrics]. 376 39

The relation of IgM rheumatoid factor (IgM-RF) and IgG immune complex (IgG-IC) to clinical aspects of mycoplasmal pneumonia was studied. Serial serum samples obtained from 20 patients with mycoplasmal pneumonia and 4 patients with Mycoplasma pneumoniae infection but without pneumonia were analyzed by sucrose density gradient centrifugation and ELISA. In this study, the following findings were obtained. With the peak concentration of IgM-RF, there was a decrease in pulmonary infiltration concomitant with a decrease in active IgG-IC. With a rapid decrease in IgM-RF, there was an exacerbation concomitant with an increase in active IgG-IC. In some cases the concentrations of IgM-RF were low in the acute phase of the disease and increased in the convalescent phase. Some patients with continuously low concentrations of IgM-RF had prolonged pneumonia. The existence of IgG-IgM-RF complexes in the bloodstream was shown. In this report, it is suggested that IgM-RF might be associated with the recovery or might play a role in the recovery from this pneumonia. Other possible explanations are also discussed.
 ...
PMID:Immunoglobulin M rheumatoid factor in patients with mycoplasmal pneumonia. 378 22

The aetiology of community-acquired pneumonia was studied by use of new bacterial and established viral serological methods besides blood culture in 162 patients. Evidence for a specific aetiology was obtained in 79 patients (49.4%). The pneumococcus was the most common aetiological agent, identified in 25.6% of cases. Other bacteria, Haemophilus influenzae, Branhamella catarrhalis, Neisseria meningitidis and Chlamydia spp. were demonstrated in 23.5%, Mycoplasma pneumonia in 1.2% and viruses in 7.4% patients. In 58% those with viral pneumonia there was evidence of mixed infection with bacteria. The predictive value of rapid laboratory tests, erythrocyte sedimentation rate, white blood cell count and C-reactive protein (CRP), was evaluated in relation to the aetiological diagnosis. They all differentiated viral from bacterial pneumonia, with CRP having the best predictive value. On the basis of these tests, most cases in which our serological tests remained negative would appear to have a bacterial aetiology also.
 ...
PMID:The aetiology of pneumonia. Application of bacterial serology and basic laboratory methods. 381 55

A new macrolide antibiotic preparation, TMS-19-Q.O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: Three hundred and seven cases were included in this report, and overall efficacy rate was 76.2%. Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.
 ...
PMID:[Clinical studies on TMS-19-Q.O tablet in respiratory tract infection]. 389 99


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>